BusinessActinium Pharmaceuticals to Present at BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 9, 2017, 12:01 PM UTC
BusinessActinium Pharmaceuticals to Present at BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 9, 2017, 12:01 PM UTC
BusinessActinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple MyelomaBy Nasdaq OMXFeb 7, 2017, 1:01 PM UTC
BusinessConverGene Announces Sponsored Research Agreement with University of Maryland, Baltimore to Evaluate First-in-class Anti-cancer AgentsBy Nasdaq OMXJan 25, 2017, 3:18 PM UTC
BusinessActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative NeoplasmsBy Nasdaq OMXJan 24, 2017, 12:01 PM UTC
BusinessActinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative NeoplasmsBy Nasdaq OMXJan 24, 2017, 12:01 PM UTC
BusinessActinium Announces Participation in Three Upcoming Hematology EventsBy Nasdaq OMXJan 20, 2017, 12:00 PM UTC
